CA
NZ
UK
AU
IND
US
…
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -1131.30M | -600.85M | -439.89M | -249.12M | -187.09M |
| Net income | -1131.30M | -600.09M | -436.37M | -248.71M | -179.77M |
| Selling general administrative | 187.13M | 97.30M | 75.62M | 40.59M | 30.45M |
| Selling and marketing expenses | - | - | 3.20M | - | - |
| Gross profit | -16.56M | -592.23M | 11.58M | 35.38M | 29.39M |
| Reconciled depreciation | 16.56M | 11.82M | 9.31M | 9.66M | 7.33M |
| Ebit | -1107.07M | -600.85M | -439.59M | -258.28M | -188.01M |
| Ebitda | -1090.51M | -589.02M | -430.28M | -249.12M | -187.08M |
| Depreciation and amortization | 16.56M | 11.82M | 9.31M | 9.15M | 0.93M |
| Non operating income net other | - | - | - | - | 0.93M |
| Operating income | -1182.37M | -689.52M | -487.19M | -258.28M | -188.01M |
| Other operating expenses | 1182.37M | 689.52M | 498.76M | 293.66M | 217.40M |
| Interest expense | 24.23M | 0.00M | 0.30M | -9.66M | 0.01M |
| Tax provision | 0.00M | -0.75M | -3.52M | -0.42M | 0.00M |
| Interest income | 90.69M | 86.88M | 47.48M | 9.15M | 0.93M |
| Net interest income | 66.46M | 86.88M | 47.18M | 9.15M | 0.92M |
| Income tax expense | - | -0.75M | -3.52M | -0.42M | -7.32M |
| Total revenue | 0.00M | 0.00M | 11.58M | 35.38M | 29.39M |
| Total operating expenses | 1165.81M | 689.52M | 498.76M | 293.66M | 217.40M |
| Cost of revenue | 16.56M | 592.23M | 411.24M | - | - |
| Total other income expense net | 51.07M | 88.68M | 47.29M | 9.15M | 0.92M |
| Net income from continuing ops | -1131.30M | -600.09M | -436.37M | -248.71M | -187.09M |
| Net income applicable to common shares | - | - | - | -248.71M | -187.09M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 2354.51M | 2558.30M | 2088.59M | 811.93M | 737.99M |
| Intangible assets | 55.80M | 56.67M | 57.74M | 58.81M | 59.88M |
| Other current assets | 49.36M | 38.33M | 25.07M | 10.57M | 6.79M |
| Total liab | 723.21M | 293.10M | 262.40M | 126.74M | 135.42M |
| Total stockholder equity | 1631.30M | 2265.20M | 1826.19M | 685.19M | 602.57M |
| Deferred long term liab | - | - | - | 0.60M | 0.50M |
| Other current liab | 209.34M | 96.61M | 74.69M | 29.45M | -20.27M |
| Common stock | 0.02M | 0.02M | 0.02M | 0.01M | 0.01M |
| Capital stock | 0.02M | 0.02M | 0.02M | 0.01M | 0.01M |
| Retained earnings | -2869.10M | -1737.80M | -1137.71M | -701.34M | -452.64M |
| Other liab | - | - | - | 7.33M | 14.65M |
| Good will | 14.61M | 14.61M | 14.61M | 14.61M | 14.61M |
| Other assets | - | - | 0.00M | 4.59M | 2.50M |
| Cash | 383.75M | 543.06M | 696.15M | 161.41M | 108.50M |
| Total current liabilities | 290.42M | 163.91M | 143.85M | 61.98M | 18.93M |
| Current deferred revenue | - | - | - | 4.46M | 18.93M |
| Net debt | -225.04M | -407.22M | -608.20M | -97.21M | -41.86M |
| Short term debt | 16.47M | 12.87M | 7.37M | 6.77M | 6.21M |
| Short long term debt total | 158.70M | 135.84M | 87.94M | 64.20M | 66.63M |
| Other stockholder equity | 4497.14M | 4001.67M | 2963.34M | 1388.30M | 317.58M |
| Property plant equipment | - | - | - | 73.74M | 71.24M |
| Total current assets | 2075.04M | 2327.63M | 1879.28M | 660.18M | 577.05M |
| Net tangible assets | - | - | - | 611.77M | 528.08M |
| Short term investments | 1641.93M | 1746.23M | 1156.81M | 483.53M | 468.56M |
| Net receivables | - | 0.00M | 1.25M | 4.67M | 5.93M |
| Inventory | - | - | 0.00M | - | -12.72M |
| Accounts payable | 64.62M | 54.43M | 61.79M | 21.31M | 14.06M |
| Accumulated other comprehensive income | 3.24M | 1.32M | 0.54M | -1.78M | -0.38M |
| Common stock total equity | - | - | - | - | 0.01M |
| Retained earnings total equity | - | - | - | - | -452.64M |
| Non currrent assets other | 43.78M | 17.57M | 7.03M | 4.59M | 15.21M |
| Non current assets total | 279.47M | 230.67M | 209.31M | 151.75M | 160.93M |
| Capital lease obligations | 158.70M | 135.84M | 87.94M | 64.20M | 66.63M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 134.05M | -554.39M | -342.60M | -24.12M | -135.59M |
| Change to liabilities | - | - | - | -7.60M | 0.58M |
| Total cashflows from investing activities | 118.06M | -554.39M | -342.60M | -24.12M | -142.12M |
| Total cash from financing activities | 621.52M | 959.41M | 1229.20M | 301.43M | 294.18M |
| Change to operating activities | - | - | - | -7.14M | 7.68M |
| Net income | -1131.30M | -600.09M | -436.37M | -248.71M | -187.09M |
| Change in cash | -158.16M | -153.08M | 534.74M | 52.91M | 4.88M |
| Begin period cash flow | 546.76M | 696.15M | 161.41M | 110.23M | 105.35M |
| End period cash flow | 388.60M | 543.06M | 696.15M | 163.15M | 110.23M |
| Total cash from operating activities | -897.74M | -557.44M | -350.57M | -224.40M | -147.18M |
| Issuance of capital stock | 347.92M | 846.35M | 385.76M | 298.05M | 291.24M |
| Depreciation | -26.96M | 11.82M | 9.31M | 9.66M | 7.33M |
| Other cashflows from investing activities | - | - | -0.00M | - | - |
| Change to inventory | - | - | - | - | 7.68M |
| Change to account receivables | 0.00M | 1.25M | 3.42M | 1.26M | 0.46M |
| Sale purchase of stock | 8.04M | 5.03M | 3.32M | 1.86M | 1.88M |
| Other cashflows from financing activities | 0.22M | 0.28M | 836.81M | 1.52M | 1.06M |
| Change to netincome | - | - | - | 28.14M | 23.86M |
| Capital expenditures | 15.99M | 10.31M | 7.73M | 10.82M | 6.53M |
| Change receivables | - | - | - | - | 0.46M |
| Cash flows other operating | - | - | - | - | 0.17M |
| Cash and cash equivalents changes | - | - | - | - | 4.88M |
| Change in working capital | 86.82M | 1.17M | 40.66M | -13.49M | 8.72M |
| Stock based compensation | 118.39M | 79.20M | 61.77M | 31.20M | 20.72M |
| Other non cash items | 55.31M | -48.77M | -22.04M | -2.64M | 3.13M |
| Free cash flow | -913.73M | -567.74M | -358.30M | -235.22M | -153.71M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| RVMD Revolution Medicines Inc |
-3.14 1.64% |
188.17 | - | - | 9035.10 | 16.87 | 8370.02 | -9.71 |
| NVO Novo Nordisk A/S |
-0.04 0.09% |
40.41 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-12.16 2.20% |
540.99 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
33.37 3.60% |
961.26 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
| Name | Title | Year Born |
|---|---|---|
| Dr. Mark A. Goldsmith Ph.D. | CEO, Pres & Chairman | 1962 |
| Mr. Jack Anders | Chief Financial Officer | 1977 |
| Ms. Margaret A. Horn J.D. | Chief Operating Officer | 1963 |
| Dr. Stephen M. Kelsey FRC Path., FRCP, M.D. | Pres of R&D | 1961 |
| Ms. Xiaolin Wang | Exec. VP of Clinical Devel. | 1971 |
| Dr. Martin D. Burke M.D., Ph.D. | Co-Founder & Chairman of Scientific Advisory Board | NA |
| Dr. Michael A. Fischbach Ph.D. | Academic Co-Founder & Member of Scientific Advisory Board | 1981 |
| Dr. Kevan M. Shokat Ph.D. | Academic Co-Founder & Member of Scientific Advisory Board | NA |
| Mr. David L. Pompliano Ph.D. | Founding Chief Scientific Officer | NA |
| Mr. Walter Reiher Ph.D. | Chief Information Officer | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.09%
Communication Services
+0.21%
Consumer Cyclical
+1.14%
Consumer Defensive
+0.88%
Energy
-2.61%
Financial Services
+0.70%
Financials
+0.41%
Healthcare
-0.75%
Industrials
+0.35%
Real Estate
+0.57%
Technology
-1.17%
Utilities
+0.05%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...